Every Form 4 that Medicus Pharma Ltd. (MDCX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MDCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDCX filings page.
Medicus Pharma Ltd. (MDCX) reported that Chief Operating Officer Smith Andrew Alasdair received equity awards on September 4, 2026. He was granted stock options for 125,000 common shares at an exercise price of $0.1705 per share, scheduled to vest quarterly in four equal installments over one year and expiring on September 4, 2031. He also acquired 735,294 common shares at $0.1705 per share, bringing his direct common share holdings to 735,458 shares and his option holdings to 125,000 shares; no Rule 10b5-1 trading plan is reported.
Medicus Pharma Ltd. (MDCX) reported that Chief Medical Officer Mehmud Faisal received an equity award on September 4, 2026. He was granted a stock option to acquire 250,000 Common Shares at an exercise price of $0.1705 per share, expiring September 4, 2031, vesting quarterly in four equal installments over one year. He also received a direct grant of 1,470,588 Common Shares at $0.1705 per share, bringing his direct common share holdings to 1,470,588 shares. No Rule 10b5-1 trading plan is reported for these awards.
Medicus Pharma Ltd. (MDCX) reported that Chief Scientific Officer Brennan Edward J. received equity awards on September 4, 2026. He was granted 100,000 stock options with an exercise price of $0.1705 per common share, expiring on September 4, 2031, and 588,235 common shares at $0.1705 per share. The option is scheduled to vest quarterly in four equal installments over one year, and his directly held common share position increased to 674,735 shares. No Rule 10b5-1 trading plan is reported for these awards.
Medicus Pharma Ltd. (MDCX) reported that its President and CFO, Carolyn F. Bonner, received equity-based compensation on September 4, 2026. She was granted options to acquire 250,000 common shares at an exercise price of $0.1705 per share, vesting quarterly in four equal installments over one year and expiring on September 4, 2031. On the same date, she also acquired 1,470,588 common shares at $0.1705 per share, resulting in direct ownership of 1,489,493 common shares. No Rule 10b5-1 trading plan is reported for these awards.
Medicus Pharma Ltd. (MDCX) reported that Chief Executive Officer and director Raza Bokhari received equity awards on September 4, 2026. He was granted 500,000 stock options to buy Common Shares at an exercise price of $0.1705 per share, expiring on September 4, 2031. These options are scheduled to vest quarterly in four equal installments over one year. On the same date, he also acquired 2,941,176 Common Shares at $0.1705 per share, all held directly, and no Rule 10b5-1 trading plan is reported.
Medicus Pharma Ltd. Chief Operating Officer Andrew Alasdair Smith received a grant of stock options covering 200,000 common shares on June 3, 2026. The options have an exercise price of $0.36 per share, vest quarterly in four equal installments over one year, and expire on June 3, 2031. Following this grant, he holds 200,000 options directly.
Medicus Pharma Ltd. director Cathy McMorris Rodgers received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. According to the footnote, the award vests quarterly in four equal installments over one year, meaning the director earns 12,500 options every quarter until fully vested. Following this grant, she holds 50,000 stock options directly, providing equity-based compensation linked to the company’s future share performance.
Medicus Pharma Ltd. director Ajay Raju received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share and were granted as a compensation award at no upfront cost. They are scheduled to vest quarterly in four equal installments over one year, giving Raju the right, once vested, to buy Medicus Pharma common shares at the fixed exercise price until the options expire in 2031.
Medicus Pharma Ltd. reported that Chief Medical Officer Mehmud Faisal received a grant of stock options covering 250,000 Common Shares. The options carry an exercise price of $0.36 per share and expire on June 3, 2031. According to the disclosure, the options were granted on June 3, 2026 and are scheduled to vest quarterly in four equal installments over one year. Following this award, Faisal holds 250,000 stock options directly.
Medicus Pharma Ltd. director May Sara R. received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. Following this grant, she holds options for 50,000 shares directly.
According to the terms, the option grant was made on June 3, 2026 and is scheduled to vest quarterly in four equal installments over one year. This is a compensation-related award, not an open-market purchase or sale of shares.
Medicus Pharma Ltd. director Patrick J. Mahaffy reported receiving a stock option grant for 50,000 underlying common shares. The option carries an exercise price of $0.36 per share, was granted on June 3, 2026, and is scheduled to vest quarterly in four equal installments over one year. The option expires on June 3, 2031, and represents a compensation-related award rather than an open-market share purchase or sale.
Medicus Pharma Ltd. director Larry Kaiser received a grant of stock options, giving him the right to acquire 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. Following this grant, he holds stock options for 50,000 shares. According to the grant terms, the options vest quarterly in four equal installments over one year, meaning the award becomes exercisable gradually rather than all at once.
Medicus Pharma Ltd. director Barry Fishman received a grant of stock options representing 50,000 common shares. The options have an exercise price of $0.36 per share and expire on June 3, 2031. They were granted on June 3, 2026 and are scheduled to vest quarterly in four equal installments over one year. Following this grant, Fishman holds 50,000 derivative securities directly.
Medicus Pharma Ltd. director Robert J. Ciaruffoli received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share, were granted on June 3, 2026, and are scheduled to vest quarterly in four equal installments over one year.
These options expire on June 3, 2031, and represent 50,000 derivative securities held by Ciaruffoli following this compensation-related award. The filing reports no open-market purchases or sales of Medicus Pharma common shares.
Medicus Pharma Ltd. reported that Chief Scientific Officer Brennan Edward J. received a grant of stock options. The award covers 25,000 options for Common Shares at an exercise price of $0.36 per share. According to the footnote, the options vest quarterly in four equal installments over one year and expire on June 3, 2031.
Medicus Pharma Ltd. President and CFO Carolyn F. Bonner received a compensation-related stock option grant covering 250,000 common shares. The option has an exercise price of $0.36 per share and expires on June 3, 2031.
According to the footnote, the award was granted on June 3, 2026 and is scheduled to vest quarterly in four equal installments over one year. Following this grant, Bonner holds stock options for 250,000 underlying common shares directly. This is an equity incentive grant rather than an open-market purchase.
Medicus Pharma Ltd. reported that Chief Executive Officer Raza Bokhari received a grant of stock options covering 500,000 underlying common shares. The options have an exercise price of $0.36 per share and were granted as a compensation-related award, not an open-market purchase.
According to the disclosure, the options were granted on June 3, 2026 and are scheduled to vest quarterly in four equal installments over one year, providing staged earning of the award. Following this grant, Bokhari holds 500,000 stock options directly, which are scheduled to expire on June 3, 2031 if not exercised.
Medicus Pharma Ltd. director Ashton William received a grant of stock options as part of his compensation. He was awarded options covering 50,000 common shares at an exercise price of $0.3600 per share. The options were granted on June 3, 2026 and are scheduled to vest quarterly in four equal installments over one year, ending on June 3, 2027. These options expire on June 3, 2031, and following this grant he holds options on 50,000 shares directly.
Medicus Pharma Ltd. reported that Chief Operating Officer Smith Andrew Alasdair received a compensation grant of stock options. The award covers 50,000 options, each giving the right to buy one common share at an exercise price of $0.50 per share. The options become exercisable on March 26, 2027 and expire on March 27, 2031. Following this grant, he holds 50,000 stock options directly.
Medicus Pharma Ltd. director Cathy McMorris Rodgers received a stock option grant covering 25,000 common shares. The options were awarded at an exercise price of $0.50 per share, carry no upfront cost, and expire on March 27, 2031. Following this grant, she holds options for 25,000 shares directly.
Medicus Pharma Ltd. director Raju Ajay received a stock option grant for 25,000 common shares. The award gives him the right to buy 25,000 shares at an exercise price of $0.50 per share. The option becomes exercisable on March 26, 2027 and expires on March 27, 2031, and his directly held option position reported in this filing totals 25,000 derivative securities.
Medicus Pharma Ltd. reported that Chief Medical Officer Mehmud Faisal received a grant of stock options as part of his compensation. The award covers 125,000 stock options, each exercisable for one common share at an exercise price of $0.50 per share. These options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031. Following this award, Faisal holds 125,000 stock options directly.
Medicus Pharma Ltd. director May Sara R. received a grant of stock options covering 25,000 underlying common shares. The options have an exercise price of $0.50 per share and can first be exercised on March 26, 2027.
These options expire on March 27, 2031. Following this grant, May Sara R. holds derivative securities representing 25,000 common shares, reflecting a compensation-related award rather than an open-market purchase.
Medicus Pharma Ltd. director Patrick J. Mahaffy received a compensation-related stock option grant, not an open-market trade. He was granted options to acquire 25,000 common shares at an exercise price of $0.50 per share. These options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031. Following this grant, he holds options for 25,000 shares directly.
Medicus Pharma Ltd. director Larry Kaiser received a grant of stock options, giving him the right to acquire 25,000 Common Shares. The options have an exercise price of $0.50 per share, become exercisable on March 26, 2027, and are scheduled to expire on March 27, 2031. Following this award, he holds 25,000 derivative securities linked to Common Shares.
Medicus Pharma Ltd. director Barry Fishman received a grant of stock options covering 25,000 common shares. The options have an exercise price of $0.50 per share, become exercisable on March 26, 2027, and expire on March 27, 2031. Following this grant, he holds 25,000 derivative securities directly.
Medicus Pharma Ltd. director Robert J. Ciaruffoli reported receiving a grant of stock options covering 25,000 underlying Common Shares. The options have a conversion price of $0.50 per share, are exercisable beginning on March 26, 2027, and expire on March 27, 2031. Following this award, he holds 25,000 stock options directly.
Medicus Pharma Ltd. Chief Scientific Officer Brennan Edward J. received a grant of stock options, giving him the right to acquire 25,000 Common Shares. The options have an exercise price of $0.50 per share and expire on March 27, 2031. Following this award, he holds 25,000 options directly.
Medicus Pharma Ltd. reported that President and CFO Carolyn F. Bonner received a grant of stock options as equity compensation. She was awarded options for 100,000 Common Shares at an exercise price of $0.50 per share, giving her the right to buy shares at that price in the future.
The options become exercisable on March 26, 2027 and expire on March 27, 2031. Following this grant, Bonner holds stock options covering 100,000 shares. This is an acquisition of derivative securities, not an open‑market purchase or sale of the company’s stock.
Medicus Pharma Ltd. Chief Executive Officer Raza Bokhari received a grant of stock options for 325,000 Common Shares. The options have an exercise price of $0.50 per share and were awarded at no cost on the grant date.
The options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031 if not exercised. Following this grant, Bokhari holds stock options covering a total of 325,000 underlying Common Shares directly as reported in this filing.
Medicus Pharma Ltd. director Ashton William received a grant of stock options, giving him the right to acquire 25,000 common shares. The options have an exercise price of $0.50 per share and expire in 2031. Following this compensation award, he holds options covering 25,000 shares directly.
Medicus Pharma Ltd. granted its Chief Operating Officer, Andrew A. Smith, a stock option award covering 50,000 common shares on December 16, 2025. The options carry an exercise price of $1.8 per share and are reported as directly owned.
The option is scheduled to vest quarterly in four equal installments over one year, giving Smith increasing rights to purchase shares over that period. Any unexercised portion expires on December 16, 2030, aligning the executive’s potential equity ownership with the company’s longer-term performance.
Medicus Pharma Ltd. reported an insider equity award involving a company director. On December 16, 2025, the director received a stock option grant covering 25,000 common shares with an exercise price of $1.8 per share. The option is scheduled to vest quarterly in four equal installments over one year, giving the recipient rights to portions of the award every three months during that period. The option expires on December 16, 2030, and following this grant the director beneficially owns 25,000 derivative securities directly.
Medicus Pharma Ltd. director Ajay Raju reported receiving a new stock option grant. On December 16, 2025, he was granted an option to purchase 25,000 Common Shares of Medicus Pharma at an exercise price of $1.80 per share. The option is scheduled to vest quarterly in four equal installments over one year, meaning the right to purchase the shares will become available in stages rather than all at once.
The option expires on December 16, 2030, giving the director a five-year window from the grant date to exercise once vested. Following this grant, Ajay Raju beneficially owns 25,000 derivative securities in the form of this stock option, held directly.
Medicus Pharma Ltd. reported that its Chief Medical Officer, Faisal Mehmud, received a stock option grant. On 12/16/2025, he was granted an option to buy 75,000 common shares at an exercise price of $1.8 per share. The option is scheduled to vest quarterly in four equal installments over one year, giving him rights to portions of the grant over time rather than all at once. The option expires on 12/16/2030 if not exercised. This filing reflects an equity-based compensation award to a senior officer, aligning part of his compensation with the company’s share performance.
Medicus Pharma Ltd. director Sara R. May reported a new equity award in the form of stock options. On December 16, 2025, she was granted a stock option covering 25,000 common shares of Medicus Pharma.
The option has an exercise price of $1.80 per share and is scheduled to vest quarterly in four equal installments over one year, giving her rights to the shares gradually rather than all at once. The option is currently shown as directly owned and is scheduled to expire on December 16, 2030 if not exercised.
Medicus Pharma Ltd. reported that director Patrick J. Mahaffy received a stock option grant on December 16, 2025. The option gives him the right to buy 25,000 common shares at an exercise price of $1.8 per share. It is scheduled to vest quarterly in four equal installments over one year, meaning the award becomes fully vested after that period. The option expires on December 16, 2030, providing a five-year window from grant date for potential exercise.
Medicus Pharma Ltd. reported an insider equity grant involving director Larry Kaiser. On December 16, 2025, he received a stock option to purchase 25,000 common shares of Medicus Pharma at an exercise price of $1.80 per share. The option is scheduled to vest quarterly in four equal installments over one year and is listed as directly owned. According to the filing, the option expires on December 16, 2030, and following this transaction Kaiser beneficially owns 25,000 derivative securities in the form of these options.
Medicus Pharma Ltd. director Barry Fishman reported receiving a stock option grant covering 25,000 common shares on 12/16/2025. The stock option has an exercise price of $1.8 per share and is scheduled to vest quarterly in four equal installments over one year from the grant date. The option expires on 12/16/2030. Following this grant, Barry Fishman beneficially owns 25,000 derivative securities in the form of these options, held directly.
Medicus Pharma Ltd. reported that director Robert J. Ciaruffoli received a stock option grant on December 16, 2025. The option gives him the right to buy 25,000 common shares at an exercise price of $1.8 per share and was granted at no upfront cost.
The option is scheduled to vest quarterly in four equal installments over one year and expires on December 16, 2030. After this grant, he beneficially owns 25,000 stock options, held directly.
Medicus Pharma Ltd. reported that its Chief Scientific Officer, Edward J. Brennan, received a stock option grant covering 50,000 common shares on December 16, 2025. The options have an exercise price of $1.8 per share and expire on December 16, 2030.
The award is scheduled to vest quarterly in four equal installments over one year, and 50,000 derivative securities are listed as beneficially owned directly following the grant.
Medicus Pharma Ltd. reported an equity award for its President and CFO, Carolyn F. Bonner. On December 16, 2025, she received a stock option grant covering 75,000 common shares at an exercise price of $1.8 per share. These options are scheduled to vest quarterly in four equal installments over one year, meaning portions of the grant become exercisable every quarter during that period.
After this grant, she held 75,000 derivative securities directly, all tied to the company’s common shares. This type of award is a common form of equity-based compensation that links an executive’s potential future gains to the company’s share performance.
Medicus Pharma Ltd. (MDCX) reported an equity award to its Chief Executive Officer and director, Raza Bokhari. On December 16, 2025, he received a stock option covering 125,000 common shares with an exercise price of $1.8 per share and an expiration date of December 16, 2030. The option is scheduled to vest quarterly in four equal installments over one year, meaning the award becomes fully vested after that period if service conditions are met. Following the grant, 125,000 derivative securities are shown as beneficially owned with direct ownership.
Medicus Pharma Ltd. reported a new stock option grant to a director. On December 16, 2025, the director received a stock option to buy 25,000 common shares of Medicus Pharma at an exercise price of $1.8 per share, expiring on December 16, 2030.
The option is scheduled to vest quarterly in four equal installments over one year, aligning the director’s potential equity ownership with short-term company performance. Following this grant, the director beneficially owns 25,000 derivative securities, held as a direct ownership position.